BIOPOR BioPorto A/S
BioPorto A/S, an in-vitro diagnostics company, focuses on developing biomarker tests to help clinicians detect the kidney injury in critically ill patients at earlier stage in Denmark, rest of Europe, North America, and Asia. It offers ProNephro AKI (NGAL), a test for pediatric acute kidney injury (AKI); NGAL Test, a particle-enhanced turbidimetric immunoassay for the quantitative determination of neutrophil gelatinase-associated lipocalin (NGAL) in human urine, EDTA plasma, or heparin plasma on automated clinical chemistry analyzers to diagnose acute kidney injury; and antibodies to develop diagnostic immunoassays within disease areas, including immunodeficiency, allergy, coagulation, diabetes, kidney, and cardiovascular disease. The company also provides ready-to-use enzyme-linked immunosorbent assay (ELISA) kits to quantify NGAL in urine, plasma, and serum; and generic Rapid Assay Device (gRAD) for custom lateral flow assays. BioPorto A/S was founded in 1917 and is based in Hellerup, Denmark.…
Industry Peers
Diagnostics & ResearchKey Statistics
About BioPorto (CPH: BIOPOR)
›
BioPorto (CPH: BIOPOR) is listed on Nasdaq Copenhagen, where its shares trade in DKK. It belongs to the Diagnostics & Research industry, part of the Healthcare sector, and reports about 44 employees.
The shares were at 0.9400 DKK on 20 November 2026, down 16.7% over 52 weeks. Its 52-week range is 0.8390 DKK to 1.380 DKK: the price is 31.9% below the high and 12.0% above the low.
Its market capitalisation is 465.39M DKK.
BioPorto reports return on equity of -130.3%, an operating margin of -35.6% and revenue down 34.8% year over year.
It holds more cash than debt, a net cash position of 68.61M DKK. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. One analyst covers the stock; their mean price target of 1.750 DKK is 86.2% above the current price.